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Introduction
Acute kidney injury (AKI) is a major complication in nearly one-third of  all cancer patients treated with 
cisplatin, a common chemotherapeutic drug used for a variety of  human cancers (1–3). The development 
of  nephrotoxicity is attributed to the rapid accumulation of  cisplatin by active transport into renal tubular 
epithelial cells, particularly in the S3 segment of  the proximal tubules (4, 5). The accumulation of  cisplatin 
causes DNA cross-linking and, in some cases, more lethal physical breaks of  the DNA (1, 6–10). These types 
of  damage to the genomic DNA play a critical role in the phenotypic changes exerted on tubular epithelial 
cells and any subsequent loss of  renal function (11, 12). To preserve normal function of  the cells, checkpoint 
systems have evolved to maintain genome stability by activating surveillance systems to ensure that damaged 
DNA from previous cell cycle phases are not transferred into mitosis. In the kidney, however, our understand-
ing of  these processes is largely undescribed, and in the case of  AKI, the activation of  certain DNA repair 
systems does not necessarily lead to a beneficial outcome to preserve or even restore renal function (13, 14).
Thyroid receptor interacting protein 13 (TRIP13) is an evolutionarily conserved family member of  the 
AAA+ ATPase enzymes (15, 16) and acts as an adapter protein with pleiotropic roles in pathways relevant 
to meiotic/mitotic checkpoint control (17–22), DNA recombination (15, 16), and double-stranded DNA 
repair (23). Insufficient production of  Trip13 can increase cell cycle blockade at the G2/M phase (23) and 
inefficiently repair double-stranded DNA breaks (16, 24, 25), which leads to the activation of  apoptotic cell 
death pathways in germline and somatic cells (16, 23–25). Moreover, TRIP13 directly activates DNA-de-
pendent protein kinase catalytic subunit (DNA-PKcs), which is a primary enzyme involved in the non-ho-
mologous end joining (NHEJ) pathway of  double-stranded DNA repair, to promote tumorigenesis (23). 
Cisplatin is a commonly used chemotherapeutic agent to treat a wide array of cancers that 
is frequently associated with toxic injury to the kidney due to oxidative DNA damage and 
perturbations in cell cycle progression leading to cell death. In this study, we investigated 
whether thyroid receptor interacting protein 13 (TRIP13) plays a central role in the protection of 
the tubular epithelia following cisplatin treatment by circumventing DNA damage. Following 
cisplatin treatment, double-stranded DNA repair pathways were inhibited using selective 
blockers to proteins involved in either homologous recombination or non-homologous end 
joining. This led to increased blood markers of acute kidney injury (AKI) (creatinine and 
neutrophil gelatinase–associated lipocalin), tubular damage, activation of DNA damage marker 
(γ-H2AX), elevated appearance of G2/M blockade (phosphorylated histone H3 Ser10 and cyclin 
B1), and apoptosis (cleaved caspase-3). Conditional proximal tubule–expressing Trip13 mice 
were observed to be virtually protected from the cisplatin nephrotoxicity by restoring most of 
the pathological phenotypes back toward normal conditions. Our findings suggest that TRIP13 
could circumvent DNA damage in the proximal tubules during cisplatin injury and that TRIP13 
may constitute a new therapeutic target in protecting the kidney from nephrotoxicants and 
reduce outcomes leading to AKI.
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In the kidney, global Trip13Gt/Gt hypomorph mice exhibit prolonged tubular epithelial cell damage follow-
ing bilateral ischemia/reperfusion injury, which is associated with increased DNA damage and activated 
apoptotic signaling (26). To date, however, the role of  TRIP13 to prevent tubular damage in other forms 
of  AKI, such as cisplatin nephrotoxicity, with respect to double-stranded breaks has yet to be studied.
In the present study, pharmacological inhibitors targeting double-stranded DNA repair pathways were 
tested to determine any interference in the normal recovery of  damaged renal tubules due to cisplatin. 
To determine whether TRIP13 could modulate this process, a transgenic mouse model was generated to 
conditionally overexpress Trip13 using the GGT1-Cre recombinase, since the main segment of  cisplatin 
nephrotoxicity is the proximal tubules. The Trip13 transgenic mice appeared normal with no evidence of  
any abnormal renal morphology or function. In the face of  AKI following cisplatin administration, the 
Trip13-expressing kidneys were largely protected from injury with no apparent loss of  renal function com-
pared to their wild-type littermates. This study provides information about TRIP13 as a renal protectant 
from nephrotoxic agents and suggests that this may be a new therapeutic target for AKI by circumventing 
double-stranded DNA breaks during the recovery of  the damaged renal tubules.
Results
Conditional Trip13 transgenic mouse model. A floxed stop codon strategy was employed to produce a condi-
tional transgenic mouse model overexpressing Trip13. A DNA-targeting construct was designed and cloned 
as shown in Figure 1A. In our approach, multiple stop codons were cloned between flanking loxP sites, 
which were placed between the CAG promoter and the transgene cassette (Trip13-T2A-EGFP). This con-
struct was injected for integration into the ROSA26 region into the zygotes, and litters were tested by 
Southern blot analysis for proper DNA banding following genomic DNA restriction digest. Founder het-
erozygote Trip13Stop/+ males and females were interbred to obtain homozygous Trip13Stop/Stop mice. GGT-Cre 
mice were used to breed with the heterozygous Trip13Stop/+ mice to generate GGT-Cre+/– Trip13Stop/+ mice. 
Subsequently, the GGT-Cre+/– Trip13Stop/+ mice were bred with the homozygous Trip13Stop/Stop mice to pro-
duce littermates of  homozygous Trip13Stop/Stop and GGT-Cre+/– Trip13Stop/Stop (Trip13ΔStop) mice for our study. 
All mice were genotyped by PCR using specific primers shown in Table 1 and a representative ethidium 
bromide–stained agarose gel showing different genotyped mouse pups (Figure 1B).
Phenotyping of  the mice was performed by detecting FLAG-tagged TRIP13 and GFP by Western blot 
analysis using protein lysates from harvested organs from female Trip13ΔStop mice (Figure 1C). FLAG and 
GFP protein were clearly detected in the kidney lysates from Trip13ΔStop mice with undetectable expression 
in the other organs tested, including duodenum, heart, lung, brain, and spleen. To determine the cell type(s) 
expressing GFP in the kidneys, we performed immunohistology using 2 different detection methods. Fluores-
cent antibodies were tested on Trip13ΔStop mouse kidneys to determine whether GFP (shown in red) (Figure 1, 
D, F, and H) would colocalize with either proximal tubule–specific lectin PVA-E (green brush border) (Figure 
1, F and G) or collecting duct marker, DBA (Figure 1H). In the Trip13Stop/Stop mouse kidneys (Figure 1G), there 
was minimal Alexa Fluor 555 intensity, demonstrating the lack of  GFP expression without the presence of  
Cre recombinase (Figure 1H). Similarly, minimal detection of  GFP signal was detected in Trip13ΔStop mouse 
kidneys in the absence of  the primary antibody (negative control image in Figure 1E). Immunostaining was 
absent in the lungs from both Trip13ΔStop (Figure 1I) and Trip13Stop/Stop (Figure 1J) mice, consistent with the lack 
of  GFP staining by Western blot analysis (Figure 1C). Similar results were obtained using DAB staining (data 
not shown), showing the segment-specific expression of  TRIP13 and GFP in our generated mouse model.
Overexpression of  Trip13 in proximal tubules prevents the loss of  renal function following cisplatin administration. 
Cisplatin (15 mg/kg IP) was administered as a single dose into female Trip13Stop/Stop and Trip13ΔStop mice, 
and tissues were harvested after 24 or 72 hours. Protein expression for GFP and FLAG-tagged TRIP13 was 
clearly detectable by Western blot analysis using kidney lysates from Trip13ΔStop mice treated with either 
vehicle or cisplatin (Figure 2A). No GFP or FLAG-tagged TRIP13 was detected in the Trip13Stop/Stop mouse 
kidneys in either treatment group (Figure 2A).
In our initial study group, no significant difference in body weight was measured in both Trip13Stop/Stop 
and Trip13ΔStop mice at 24 (n = 11) and 72 hours (n = 6) following vehicle treatment (data not shown). At 
24 hours, there was a modest 5.4% decrease in body weight after which the body weight slightly increased 
above the pretreatment weight by 7.4% at 72 hours. At 24 and 72 hours following cisplatin treatment, the 
body weight in the Trip13Stop/Stop mice was progressively lower by 8.4% (n = 11) and 25.1% (n = 6), respec-
tively, compared with pretreatment measurements, whereas the Trip13ΔStop mice had a lesser decrease in 
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Figure 1. Genomic targeting construct of Trip13 overexpression. (A) Targeting construct was designed for inte-
gration into the ROSA26 region, and the expression cassette was designed with the CAG promoter-floxed stop 
codon-Trip13 cDNA-T2A-EGFP-polyA. 2A, protease cleavage site (Trip13 cDNA was FLAG tagged at the 3′ end); CAG, 
CMV-IE enhancer/chicken β-actin/rabbit β-globin. (B) Genomic DNA isolated from mouse pups was PCR analyzed 
using specific primers to differentiate wild-type, floxed stop, and Cre-containing mice. Wild-type (WT) = 453 bp; 
floxed stop (flox) = 616 bp; and Cre = 400 bp. M = 1 kb ladder; lanes 1, 4, and 7 = F1/R1 primers (wild-type); 2, 5, and 
8 = F2/R1 primers (floxed Trip13); and 3, 6, and 9 = GGT1-Cre primers (Cre); Trip13st/st, Trip13Stop/Stop. (C) Western blot 
analysis of FLAG-tagged TRIP13 and GFP protein expression in harvested tissues from Trip13ΔStop mice. GAPDH was 
shown as a loading control. K, kidney; Duo, duodenum; Hrt, heart; Br, brain; Lu, lungs; Spl, spleen. (D–H) Immuno-
fluorescence was performed on FFPE Trip13Stop/Stop and Trip13ΔStop kidneys to detect GFP expression. GFP was detected 
by Alexa Fluor 555 fluorescence (red color) in (G) Trip13Stop/Stop and (D, F, and H) Trip13ΔStop kidneys. E shows a negative 
control kidney section incubated without primary GFP antibody (no primary). To determine proximal tubules (F and 
G) or collecting ducts (H), Alexa Fluor 488 (green) fluorescence was detected using PVA-E (brush border of proximal 
tubules) or DBA (collecting ducts). Nuclei were stained with DAPI (blue). Dashed lines in F indicate PVA-E–positive 
tubules with minimal to undetectable expression of GFP, showing mosaicism of Cre expression. (I and J) Immuno-
histochemical staining for GFP in cisplatin-treated Trip13ΔStop and Trip13Stop/Stop mouse lungs. All DAB-stained sections 
were counterstained with hematoxylin. Scale bar: 200 μm (D, E, I, and J), 100 μm (F–H). PVA-E, Phaseolus vulgaris 
erthyroagglutinin; DBA, Dolicus biflorus agglutinin.
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body weight (13.9%) after 72 hours. The changes in body weight were associated with the extent of  AKI 
by monitoring the blood chemistry for AKI markers, creatinine (Figure 2B) and neutrophil gelatinase-as-
sociated lipocalin (NGAL) (Figure 2C), and calculating the tubular damage (Figure 2, D–H).
Serum creatinine was significantly elevated in female Trip13Stop/Stop mice treated with cisplatin (1.95 ± 0.32 
mg/dL; n = 6) compared with vehicle-treated littermates (0.11 ± 0.1 mg/dL; n = 6; Figure 2B). In the consti-
tutive proximal tubule TRIP13-expressing (Trip13ΔStop; n = 8) mice following cisplatin administration, serum 
creatinine values were only slightly elevated (0.16 ± 0.01 mg/dL; n = 8) compared with the vehicle-treated 
mice (0.09 ± 0.01 mg/dL; n = 4) but significantly lower (P < 0.05) than those measured from the Trip13Stop/Stop 
mice (n = 6). A similar trend was detected for serum NGAL levels, which rose to 240.0 ± 34.5 ng/L (n = 6) 
in cisplatin-treated Trip13Stop/Stop mice but were markedly attenuated in the Trip13ΔStop mice (Figure 2C; n = 8).
Histological analyses of  kidney sections were scored for tubular damage in all mouse groups following 
treatment with a single dose of  either vehicle or cisplatin (Figure 2D). Tubular damage was rare or complete-
ly nonexistent in vehicle-treated Trip13Stop/Stop mice kidneys after 24 (n = 5; Figure 2D) or 72 hours (n = 6; 
(Figure 2, D and E) and Trip13ΔStop mice kidneys after 72 hours (n = 4) (Figure 2, D and G). In cisplatin-treat-
ed Trip13Stop/Stop mice, there was a significantly higher number of  damaged tubules (40.1% ± 6.9%; n = 8; 
Figure 2, D and F) as determined by the presence of  dilated and cast-containing tubules compared with the 
Trip13ΔStop mouse kidneys, which exhibited few damaged tubules (0.4% ± 0.1%; n = 8; Figure 2, D and H).
Cisplatin-dependent activation of  DNA damage response pathway in mouse kidneys. Phosphorylated H2AX 
(γ-H2AX; Ser139) was detected at 24 and 72 hours after cisplatin treatment, indicating DNA damage response 
activation (Figure 3). Renal tubular epithelial cells positive for γ-H2AX were rarely detected in vehicle-treated 
Trip13Stop/Stop mouse kidneys at both 24 (Figure 3, A and H) and 72 hours (Figure 3, E and H; 0.1%–0.2%; n 
= 5–6/time point). At 24 hours, cisplatin-treated Trip13Stop/Stop mice had a high number (84.7% ± 5.6%; n = 5) 
of  the tubular epithelial cells positive for γ-H2AX (Figure 3, B and H). At 72 hours, the number of  γ-H2AX–
positive tubular epithelial cells decreased from day 1 but remained elevated (56.3% ± 7.5%; n = 6) in the 
cisplatin-treated Trip13Stop/Stop mice (Figure 3, D and H). In the Trip13ΔStop mice, there was a significantly lower 
percentage of  γ-H2AX–positive tubular epithelial cells (14.0% ± 4.0%; P < 0.05; n = 8) following treatment 
with cisplatin after 72 hours (Figure 3, F and H). Rare activation of  γ-H2AX was detected (0.2% ± 0.1%; n 
= 4) in vehicle-treated Trip13ΔStop mouse kidneys (Figure 3, E and H). No γ-H2AX–positive tubular epithelial 
cells were detected in the negative control section without the antibody (Figure 3G).
To determine whether other nucleotide modifications were observed following cisplatin administration, 
we performed immunofluorescence on the kidney sections for 8-hydroxy-2′-deoxyguanosine (8-OHdG), 
which is a common variant observed during oxidative stress–related damage. At 72 hours, 8-OHdG was 
readily detected in the cisplatin-treated Trip13Stop/Stop mouse kidneys (Figure 3J), whereas no nuclei were 
positive for 8-OHdG in the vehicle-treated mouse littermates (Figure 3I). In the Trip13ΔStop mice, there was 
no detection of  8-OHdG in the vehicle-treated kidneys (Figure 3K) and considerably less intense fluores-
cence for 8-OHdG–positive nuclei following cisplatin treatment (Figure 3L).
The temporal activation of  γ-H2AX following cisplatin treatment was associated with increased 
G2/M blockade using phosphorylated (p-) histone H3 (Ser10; Figure 4, A–F), increased accumulation of  
cyclin B1, and proapoptotic signaling by detecting cleaved caspase-3–positive tubular epithelial cells (Fig-
ure 4H). More specifically, the number of  p–histone H3–positive (Ser10-positive) nuclei in tubular epithe-
lia was significantly higher (P < 0.01) in cisplatin-treated Trip13Stop/Stop mice (18.9 ± 5.0 nuclei/image; n = 
6; Figure 4, B and F) compared with both the vehicle-treated Trip13Stop/Stop (1.0 ± 0.3 nuclei/image; n = 6; 
Table 1. PCR primers for genotyping
Primer name Sequence
F1 5′-CACTTGCTCTCCCAAAGTCGCTC-3′ 616 bp
F2 5′-AGATGTACTGCCAAGAGGAAAGTC-3′ 453 bp
R1 5′-ATACTCCGAGGCGGATCACAA-3′
Cre forward 5′-GAACGCACTGATTTCGACCA-3′ 204 bp
Cre reverse 5′-GCTAACCAGCGTTTTCGTTC-3′
GGT1-Cre (forward) 5′-CCTGGAAAATGCTTCTGTCCG-3′ 400 bp
GGT1-Cre (reverse) 5′-CAGGGTGTTATAAGCAATCCC-3′
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Figure 4, A and F) and Trip13ΔStop (1.1 ± 0.6 nuclei/image; n = 4; Figure 4, C and F) mouse groups. In 
the cisplatin-treated Trip13ΔStop mice, there was a significantly (P < 0.01) lower number of  p–histone H3–
positive (Ser10-positive) cells (2.8 ± 1.5/image; n = 8; Figure 4, D and F) compared with vehicle-treated 
littermates. No positive cells were detected in the negative control (no antibody) sections (Figure 4E).
Figure 2. Trip13 overexpression in the proximal tubules provides protection from renal tubular epithelial cell damage 
following cisplatin administration. Mice were injected with a single injection of vehicle (20% captisol in saline) or cispla-
tin (15 mg/kg IP), and kidneys and blood were harvested to detect markers of renal dysfunction. (A) Kidney samples from 
homozygous floxed stop (Trip13Stop/Stop) and Trip13ΔStop mice were harvested from mice treated with either vehicle (-Cis; 20% 
captisol) or cisplatin (+Cis; 15 mg/kg IP) after 72 hours following the initial injection. Western blot analysis was performed 
using FLAG and GFP primary antibodies. GAPDH was used as a loading control. Arrows on the right side of the panel 
indicate protein standard size. (B) Serum creatinine and (C) NGAL was measured in each mouse group. (D) Percentage of 
tubular damage was determined in each group. (E–H) Representative histological images from (E and G) vehicle- or (F and 
H) cisplatin-treated (15 mg/kg IP) Trip13Stop/Stop (E and F) and Trip13ΔStop (G and H) mice. Tubular epithelial cell damage was 
scored as a percentage of total tubules counted. — = vehicle; + = cisplatin. *P < 0.05, ****P < 0.0001 between all other 
groups using 1-way ANOVA with Tukey’s post hoc analysis. n = 4–8 animals per group. Scale bar: 200 μm (E–H).
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The increase in G2/M-positive tubular epithelial cells at 72 hours after cisplatin treatment was associat-
ed with a considerable increase in band intensity of  cyclin B1 (Figure 4G) compared with vehicle treatment 
in the Trip13Stop/Stop kidneys. In the Trip13ΔStop kidney lysates, endogenous levels of  cyclin B1 were elevated 
under normal conditions with no significant difference in the cyclin B1 accumulation in the cisplatin-treat-
ed Trip13ΔStop kidney lysates.
We found asignificantly higher percentage (4.5% ± 0.9%; n = 5; P < 0.0001) of  cleaved caspase-3–
positive nuclei in cisplatin-treated Trip13Stop/Stop mice compared with the proximal tubular TRIP13-over-
expressing Trip13ΔStop mouse kidneys (0.5% ± 0.2%; n = 7) (Figure 4H). Rare positive cells for cleaved 
caspase-3 were evident in vehicle-treated Trip13Stop/Stop kidneys at both 24 (0.04% ± 0.02%; n = 5) and 
72 hours (0.2% ± 0.1%; n = 6), or 24 hours following cisplatin treatment (0.08% ± 0.1%; n = 5; Figure 
4H). Tubular epithelial cell proliferation was determined by staining with Ki67 and/or proliferating cell 
nuclear antigen (PCNA) staining (Supplemental Figure 1; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.139092DS1). There was a significantly higher percent-
age of  Ki67-positive nuclei by ~3.2-fold (P < 0.001) in the cisplatin-treated Trip13Stop/Stop mouse kidneys 
(3.7% ± 0.5%; n = 4) compared with the vehicle-treated Trip13Stop/Stop group (1.2% ± 0.1%; n = 6). In the 
vehicle-treated Trip13ΔStop mouse kidneys where Cre activation induced selective proximal tubular Trip13 
expression, the percentage of  Ki67-positive cells (1.1% ± 0.2%; n = 4) was not significantly different from 
the control Cre-minus Trip13Stop/Stop mouse kidneys. Cisplatin treatment produced a small, but insignif-
icant, increase in the Ki67-positive nuclei from the Trip13ΔStop mouse kidneys (1.6% ± 0.2%; n = 8). A 
similar profile in PCNA-positive nuclei was observed in the same kidneys (Supplemental Figure 1).
In male mice, cisplatin at the same dose administered to females tended to have a slower and 
less potent effect on body weight and kidney damage (Supplemental Figure 2). Serum creatinine was 
Figure 3. Constitutive TRIP13 overexpression in the proximal tubules reduces activation of DNA damage following cisplatin administration. 
Following cisplatin treatment (15 mg/kg IP), kidneys were harvested after 1 or 3 days for immunohistochemistry of (A–H) γ-H2AX (Ser139) and (I–L) 
8-hydroxy-2′-deoxyguanosine (8-OHdG). After 24 (A and B) and 72 (C–F) hours following cisplatin administration, γ-H2AX (Ser139) was detected in (A–D) 
Trip13Stop/Stop and (E and F) Trip13ΔStop mice and quantified by counting positive nuclei. Sections were counterstained with hematoxylin. Negative control 
(no primary antibody) is shown (G) using sections from Trip13ΔStop mice treated with cisplatin at day 3. (H) Graphical analysis of γ-H2AX (Ser139) as a per-
centage of total nuclei. — = vehicle; + = cisplatin. ***P < 0.001, ****P < 0.0001 between the indicated groups using 1-way ANOVA with Tukey’s post hoc 
analysis. (I–L) Immunofluorescence of 8-OHdG in kidney sections from vehicle- and cisplatin-treated Trip13Stop/Stop and Trip13ΔStop mice after day 3. Alexa 
Fluor 555 (red) fluorescence was used to detect 8-OHdG, and Alexa Fluor 488 (green) fluorescence was used to detect proximal tubule lectin (PVA-E). 
DAPI was used to detect nuclei (blue). Scale bar: 200 μm (A–G); 100 μm (I–L). n = 4–8 animals per group.
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significantly lower (P < 0.001) at 0.8 ± 0.2 mg/dL (n = 8) in males compared with 1.95 mg/dL (n = 
6) in females (Figure 2B) after 72 hours. Similarly, γ-H2AX (24.9% ± 1.9%; n = 8) was significantly 
lower (P < 0.0001) by more than 50% in males compared with the females (56.3% ± 7.5%; Figure 
3H), and this was associated with less tubular damage (29.4% ± 5.0%; n = 8) by approximately 25% 
than females (Figure 2D).
Blockade of  double-stranded DNA repair exacerbates cisplatin-dependent tubular damage. To evaluate wheth-
er the recovery of  DNA damage associated with cisplatin nephrotoxicity required double-stranded DNA 
break repair pathway activation, selective inhibitors to homologous recombination (mirin) or NHEJ 
(NU7441) were administered to determine the effects on tubular damage and renal function.
Mirin is a selective inhibitor of  Mre11-mediated homologous recombination (27), with relatively poor 
solubility for in vivo studies. To improve the bioavailability of  mirin, a nanoparticle formulation was pre-
pared similarly to a prior study (28) and injected into the mice (50 mg/kg IP) immediately following the 
injection of  cisplatin (15 mg/kg IP). As a control, nanoparticles devoid of  mirin were injected in a separate 
group of  mice. The chemical properties of  the nanoparticles are shown in Supplemental Figure 3. As a 
proof  of  concept, the nanoparticle formulation (50 μg) with indocyanine green (ICG) dye demonstrated 
Figure 4. Constitutive TRIP13 overexpression reduces apoptotic signaling and regulates intracellular signaling 
pathways. (A–E) Representative images are shown for p–histone H3 (Ser10) in kidney sections obtained from vehi-
cle- and cisplatin-treated Trip13Stop/Stop (A and B) and Trip13ΔStop (C and D) mice after day 3. Arrowheads are pointing at 
individual or clusters of stained nuclei. (E) A negative control (no primary antibody) section was used from a cispla-
tin-treated Trip13Stop/Stop mouse. (F) Graphical analysis showing quantitative numbers of nuclei positive for p–histone 
H3 (Ser10) in each image (3–4 images were counted per kidney section in each mouse). (G) Cyclin B1 bands were 
shown following Western blot analysis using kidney lysates isolated from Trip13Stop/Stop and Trip13ΔStop mice treated 
with either vehicle or cisplatin (15 mg/kg IP) after 72 hours. (H) Cleaved caspase-3–positive cells were counted rela-
tive to the total number of nuclei. — = vehicle; + = cisplatin (15 mg/kg IP). *P < 0.01 between all groups using 1-way 
ANOVA with a Tukey’s post hoc analysis. Scale bar: 100 μm (A–D), 200 μm (E). n = 4–8 animals/group.
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predominantly strong signal in intact mouse kidneys (Figure 5A) and following organ harvesting (Figure 
5B) after 24 hours following IP administration. Figure 5C provides quantitative fluorescence in the isolated 
organs of  the injected mice after 24 hours, which showed that the kidney was about 4 times higher in fluo-
rescence compared with the other organs, including the liver, lung, spleen, and heart.
Using the nanoparticle formulation in cisplatin-treated male Trip13Stop/Stop mice, the nanoparticle for-
mulation containing mirin (NP-Mirin) exerted significantly increased (P < 0.05) tubular damage (Figure 
5, D–G) and serum markers of  AKI (creatinine and NGAL) (Figure 5, H and I) after 72 hours compared 
with their control littermates treated with nanoparticles (NP-Ctrl). In this group, the lower creatinine levels 
following cisplatin treatment on day 3 are probably attributed to a combination of  the use of  males rather 
than females as well as the relatively high volume of  NP solution (~0.7–1 mL) needed for injection into 
the mice. Consistent with the increased physical damage and serum markers of  AKI, γ-H2AX–positive 
(Ser139-positive) cells were significantly higher (P < 0.01) in the NP-Mirin (40.9% ± 3.5%; n = 7) versus 
NP-Ctrl group (17.5% ± 4.0% cells; n = 5) (Figure 5J). Overexpression of  proximal tubular TRIP13 pre-
vented the tubular damage even in the presence of  mirin, and this was associated with lower serum cre-
atinine (0.23 ± 0.04 mg/dL; P < 0.05), lower NGAL measurement (38.1 ± 8.5 ng/mL; n = 5; P < 0.05), 
and fewer γ-H2AX–positive cells (20.0% ± 5.8%; n = 5; P < 0.05). No statistical difference was calculated 
between the different groups for PCNA-positive nuclei regardless of  the TRIP13 status (Figure 5K).
In addition, in the mice treated with both mirin and cisplatin, there was a significant ~2-fold increase 
(P < 0.01; n = 4 mice/group) in DNA-PKcs mRNA levels compared with vehicle-treated mice (Figure 5L; 
n = 4/group), which suggests a potential effect by the NHEJ pathway to compensate for DNA repair when 
the homology directed repair pathway is partially to completely blocked.
To evaluate the role of  the NHEJ pathway during cisplatin injury, a selective inhibitor to the 
DNA-PKcs, NU7441 (20 mg/kg IP), was tested in a separate group of  male Trip13Stop/Stop mice. The 
experimental time was shortened compared with the other groups because of  the 30% mortality rate 
that was occurring within 48 hours after treatment with both cisplatin and NU7441 in the Trip13Stop/Stop 
mice. All other non-NU7441-treated groups only exhibited observations of  morbidity, but not mortal-
ity, prior to day 3 following cisplatin treatment.
Administration of  NU7441 with vehicle solution for cisplatin (~0.1 mL) was injected at time 0 and at 
24 hours, and the mouse kidneys were harvested after 48 hours. No adverse change in tubular architecture 
(Figure 6, A–E) or renal function (0.09 ± 0.02 mg/dL; n = 7; Figure 6F) was observed. Following treatment 
with cisplatin (15 mg/kg IP), the NU7441-treated Trip13Stop/Stop mice had significantly higher (P < 0.001) 
serum creatinine (1.47 ± 0.49 mg/dL; n = 7) after 48 hours compared with cisplatin-treated littermates 
without NU7441 (0.07 ± 0.01 mg/dL; n = 6). Tubular damage was consistent with the serum creatinine 
values where the NU7441-treated mice exhibited significantly higher tubular damage (63.5% ± 16.1%; P 
< 0.01; n = 7) compared with mice only treated with cisplatin and vehicle (9.8% ± 2.8%; n = 7) or vehicle 
alone (n = 7) (Figure 6, A–E). Similarly, there was a tremendously higher number of  γ-H2AX–positive 
nuclei (Figure 6G) in the cisplatin-treated Trip13Stop/Stop with (36.5% ± 1.2%; n = 7) or without NU7441 
(1.5% ± 0.4%; n = 7). Minimal activation of  γ-H2AX was detected in control Trip13Stop/Stop mice treated 
only with NU7441 (0.2 ± 0.1; n = 7). In the Trip13ΔStop mice (n = 4), cisplatin with NU7441 treatment did 
not lead to any measurable change in serum creatinine (0.11 ± 0.02 mg/dL) (Figure 6F) or γ-H2AX–posi-
tive nuclei (1.8% ± 0.8%; n = 4) (Figure 6G) and only 9.5% ± 2.0% (n = 4) of  tubular damage after 48 hours 
(Figure 6, D and E). In cisplatin-treated Trip13Stop/Stop mice, treatment with NU7441 led to a small, but 
significant (P < 0.05), reduction in Ki67-positive nuclei (1.0% ± 0.1%; n = 6) compared with vehicle-treated 
mice (1.9% ± 0.3%; n = 6) (Figure 6H). No significant difference in Ki67-positive nuclei was calculated 
between cisplatin-treated Trip13Stop/Stop (1.0% ± 0.1%; n = 7) and Trip13ΔStop (1.5% ± 0.1%; n = 4) mice treat-
ed with NU7441. In the absence of  cisplatin, Trip13Stop/Stop mice treated only with NU7441 had a modest, 
but significantly higher, number of  Ki67-positive nuclei (P < 0.05; 1.8% ± 0.2%; n = 6).
Discussion
In the present study, constitutive de novo overexpression of  TRIP13 in proximal tubules provided consid-
erable protection to the kidney from acute nephrotoxic effects of  cisplatin. Even though cisplatin or other 
platinum-based compounds remain commonly prescribed to combat various types of  cancer because of  
their continued effectiveness, with constant daily use, these drugs can accumulate in the proximal tubules 
and often produce deleterious acute effects in the kidney.
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One of  the major consequences of  cisplatin accumulation is the formation of  reactive oxygen species 
leading to genomic DNA modifications at the nucleotide level that can even produce lethal physical breaks 
in the DNA. Consistent with this finding, we observed increased fluorescent nuclei for 8-OHdG, which is a 
biomarker for oxidative damage (29) and can be an indicator for clustered DNA lesions that could indicate 
double-stranded DNA breaks (DSBs) (30). Another early response to the DNA damage, including DSBs, 
is the phosphorylation of  a histone variant H2A (γ-H2AX) by distinct sensors (31), such as ataxia telangi-
ectasia mutated (ATM) (32, 33), which is a primary mobilizer of  the cellular response to DSBs. Due to the 
pleiotropic effects induced by cisplatin on DNA, other sensors may be activated by crosstalk mechanisms 
with ATM, including ataxia telangiectasia and Rad3 related (ATR) and DNA-PK, to control not only the 
phosphorylation of  H2AX (34), but also other downstream transducers (35). In general, a majority (about 
two-thirds) of  the cells that are destined to survive progress through the S phase of  the cell cycle and exit 
mitosis. This would lead to the formation of  new and properly oriented epithelial cells (36, 37). To achieve 
Figure 5. Inhibition of double-strand break repair promotes tubular epithelial cell damage. (A and B) Nanoparticles 
(50 μg) containing fluorescent ICG dye were injected into mice and monitored 24 hours later using IVIS system in (A) 
living mice and (B) ex vivo excised organs. (C) Ex vivo organ fluorescence accumulation (n = 3 animals). K, kidney; Lu, 
lung; Liv, liver; H, heart; Spl, spleen. Data represent mean ± SD. (D–G) Representative histological images from (D) vehi-
cle- or (E and F) cisplatin-treated (15 mg/kg IP) Trip13Stop/Stop (D and E) and Trip13ΔStop (F) mice. (G) Tubular epithelial cell 
damage was scored as a percentage of total tubules counted. Serum markers of AKI were monitored for (H) creatinine 
and (I) NGAL after 72 hours following treatment with cisplatin (15 mg/kg IP) and NP-mirin or NP-Ctrl (50 mg/kg IP). (J) 
γ-H2AX– (Ser139) and (K) PCNA-positive nuclei in kidney sections at 72 hours following cisplatin treatment with and 
without mirin. NP without mirin (50 mg/kg IP) was used as the control solution. (L) Relative gene expression change 
following treatment with cisplatin and/or mirin. Each of the respective groups was compared with mouse kidney values 
obtained from control vehicle-treated Trip13Stop/Stop mice. (G–K) n = 5–7 mice/group; (L) n=4 mice/group. *P < 0.05, **P < 
0.01 between all organs (C) or indicated groups (G, I, J, and L) or all groups (C) using 1-way ANOVA with Tukey’s post hoc 
analysis. Significance for creatinine (H) was determined using Kruskal-Wallis nonparametric test with Dunn’s post hoc 
analysis. Scale bar: 100 μm. + = administration of cisplatin or mirin; Cre - = Trip13Stop/Stop; Cre + = ΔStop.
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this level of  recovery, the fate of  the surviving tubular epithelial cells is determined by arresting the cell 
cycle at distinct points, such as the intersection of  G1/S and G2/M stage. This enables cells to make a 
decision on whether to activate pathways to restore normal cellular function and become mitotically active 
or undergo apoptotic cell death (38, 39). However, prolongation of  G2/M arrest, which occurs in various 
forms of  AKI, can tilt the balance of  the cellular fate toward cell death (40). This would inevitably slow or 
produce incomplete recovery and lead to further deterioration in renal function (38, 39).
At present, the upstream signaling pathways involved with TRIP13 during DNA damage repair in 
the mammalian system have yet to be fully described. In cultured tubular epithelia, cisplatin preferentially 
activates the ATR/Chk2 signaling axis to promote renal cell apoptosis through TP53 activation (41). More 
recently, proximal tubule knockout of  ATR resulted in increased tubular damage, DNA damage, fibrosis, 
and a loss of  kidney function following kidney injury, which was associated with increased production of  
Figure 6. Inhibition of DNA-PKcs accelerates AKI. NU7441 (20 mg/kg) was administered IP to Trip13Stop/Stop and 
Trip13ΔStop mice that were euthanized prior to or at 48 hours to collect blood and kidneys. (A–D) Representative his-
tological images from (A) vehicle- or (B–D) cisplatin-treated (15 mg/kg IP) Trip13Stop/Stop (A–C) and Trip13ΔStop (D) mice 
coadministered with either vehicle (B) or NU7441 (20 mg/kg IP; A, C, and D). (E) Tubular epithelial cell damage was 
scored as a percentage of total tubules. **P < 0.01 between all groups. (F) Serum markers of AKI were measured for 
creatinine after 48 hours following treatment with cisplatin (15 mg/kg IP). *P < 0.05; **P < 0.01 between cisplatin- and 
NU7441-treated mice. Positive nuclei for (G) γ-H2AX (Ser139) and (H) Ki-67 in kidney sections at 48 hours following cis-
platin treatment with and without NU7441. *P < 0.05 between both genetic strains treated with cisplatin- and NU7441; 
***P < 0.001 between all groups. One-way ANOVA with Tukey’s post hoc analysis was performed for each set of data 
(E–H). n = 4–7 mice/group. Scale bar: 100 μm. ΔStop, Trip13ΔStop mice; Trip13St/St, Trip13Stop/Stop mice.
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p53 and p21 (42). In oocytes with reduced endogenous production of  TRIP13, partial activity of  TP53 
and its paralog, TAp63, was detected, leading to increased apoptotic cell death due to incomplete dou-
ble-stranded DNA repair (25). A previous study from our lab also showed that injured tubular epithelial 
cells could activate phosphorylated forms of  TP53 (26), and this mechanism was linked to a direct interac-
tion between TRIP13 and tetratricopeptide 5, which is a coactivator of  p53 (26). Depending upon the type 
and extent of  DNA damage, TRIP13 may be a key regulator in controlling the pathways involved in DNA 
repair and cell cycle progression, especially since hypomorph TRIP13 mice were unable to completely 
repair their germline DNA, resulting in their fate being directed toward apoptosis (25). Further studies are 
needed to explore how sensors and effectors normally associated with dSBs, namely ATM and DNA-PKcs, 
are involved with TRIP13.
With that said, TRIP13 overexpression has been shown to promote a more aggressive state of  growth in 
somatic head and neck cancer cells by activating double-stranded DNA repair through the NHEJ pathway 
(23). In that study, TRIP13 promoted DSB repair by directly binding and activating DNA-PKcs (23). In 
general, NHEJ is considered the predominant pathway by which DSBs are repaired, particularly in lowly 
mitotic cells (43). However, other pathways exist, such as homologous recombination, to ensure high-fidelity 
repair following DNA damage. Emerging data that suggest TRIP13 acting as an AAA+ ATPase can remodel 
protein conformations to actively switch the specific pathway involved in double-stranded DNA repair. For 
example, Rev7-Shieldin complexes, which normally activate NHEJ pathways, can be dissociated by TRIP13 
through a conformational change in Rev7 (44–46). This leads to a transition where the double-stranded DNA 
repair is performed by homology-dependent recombination instead of  NHEJ (44–46). A similar switch to 
homologous recombination occurs when TRIP13 dissociates Rev3-Rev7 complexes, which normally activate 
the translesion synthesis (TLS) pathway (44, 47). In our study, TRIP13 overexpression in the proximal tubules 
may have been able to interchangeably swap DNA repair pathways following cisplatin injury in the presence 
of  selective pathway inhibitors, which led to the limited tubular damage and preserved kidney function.
In addition to DNA repair, TRIP13 is involved in the regulation of  the mitotic checkpoint com-
plex (MCC) (17–21, 48–51), which comprises a heterotetrameric protein complex that functions as 
the primary inhibitor of  the spindle assembly checkpoint (SAC). The SAC process maintains genome 
stability by delaying anaphase until metaphase chromosomes are properly aligned with spindle attach-
ment (52). In the case of  cisplatin treatment, damaged kidney cells may be arrested at different phases 
of  the cell cycle, including G2/M, where the MCC would form and bind to the anaphase-promoting 
complex or cyclosome (APC/C) to inhibit the SAC. To disassemble the MCC, TRIP13 performs a 
series of  mechanistic steps, which includes binding to p31comet and hydrolyzing ATP through its ATPase 
activity, to facilitate a conformational change in a key MCC protein, mitotic arrest defective protein 
2 (Mad2), from an active closed (C-Mad2) to an inactive open (O-Mad2) state (17–21, 48–51). This is 
an important regulatory step as the formation of  an active MCC is dependent upon the interaction of  
C-Mad2 with CDC20, which is part of  the MCC that binds to APC/C and prevents SAC activation. In 
vitro experiments have shown that the TRIP13 is only capable of  disassembling free MCC that is not 
bound to the APC/C (51). This context-dependent effect by TRIP13 may be important during condi-
tions of  mitotic arrest, where TRIP13 levels were essential in determining the length of  mitosis; i.e., in 
the absence of  TRIP13, mitotic length was considerably reduced whereas overexpression of  TRIP13 
rescued the mitotic length of  the cell (18). Unperturbed mitosis is not dependent on the regulatory 
actions of  TRIP13 (18). Another factor that could affect both DNA repair and mitotic progression is 
the potential competition in binding p31comet by either homodimer Rev7 or Mad2. The interaction by 
p31comet with Rev7 instead of  Mad2 could affect mitotic exit by dysregulating the control of  the SAC by 
MCC. Alternatively, p31comet sequestration of  Rev7 from its normal binding partner, Rev3, could limit 
the ability of  the damaged DNA to recover using the TLS pathway following cisplatin exposure (53). 
This may partially explain some of  our observations where TRIP13 overexpression led to an increased 
accumulation of  cyclin B1 in normal kidneys. A constant pool of  inactive O-Mad2 may have been pro-
duced from C-Mad2, which would have led to the dissociation of  the non-APC/C-bound MCC into its 
individual constituents. Upon exposure to an injurious stimuli, like cisplatin, the mitotic length may not 
have been negatively affected or even blocked due to the absence of  free MCC. This may have enabled 
a higher number of  injured cells to continue with their DNA repair, especially being potentiated by 
TRIP13 overexpression. In the end, this may have directed the fate of  the initially damaged cell toward 
survival rather than death due to the more efficient repair of  the damaged DNA.
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In conclusion, our study demonstrated the production and testing of a floxed stop (LSL) mouse model that 
can selectively induce Trip13 expression for in vivo investigation in the kidney, and potentially for other organs 
in normal and injury states. Here, we present data that constitutive overexpression of TRIP13 in the proximal 
tubules following cisplatin administration prevented the increased phosphorylation of H2AX in conjunction 
with reduced blockade at the G2/M phase of the cell cycle. It would appear that normal tubular epithelia are 
in a higher state of mitotic activity presumably due to TRIP13 overexpression in vivo. This may have promot-
ed cell survival and limited apoptotic cell death from the nephrotoxic effects of cisplatin. Since TRIP13 was 
detected in normal and AKI human kidney sections (Supplemental Figure 4) similar to our findings in mice 
(26), TRIP13 or its associated binding proteins may become potential therapeutic targets to protect the kidney 
from not only cisplatin nephrotoxicity but also possibly other forms of acute and chronic kidney disease.
Methods
Generation of  conditional transgenic mice to express Trip13. Conditional Trip13-transgenic mice were generated 
using a floxed stop strategy (Cyagen). The targeting construct was designed (from 5′ to 3′) as follows: a 5′ 
homology arm, a ubiquitously expressed CAG hybrid promoter, a loxP-flanked 3xSV40 poly(A) stop cas-
sette, a 3X-FLAG epitope tag fused to Trip13, a T2A ribosomal skip cleavage peptide sequence, an EGFP 
gene, a bovine growth hormone poly(A), and a 3′ homology arm. The mouse expressing γ-glutamyl trans-
peptidase–Cre recombinase mouse was bred into the homozygous lox-Stop-lox-Trip13-GFP (Trip13Stop/Stop) 
mouse to produce the conditional GGT1-Cre+/– Trip13-GFP (Trip13ΔStop) mice. Mice were housed, bred, 
and maintained in a specific pathogen–free animal facility at the University of  Tennessee Health Science 
Center. All experiments were approved by the IACUC (see Study approval). Mice were allowed ad libitum 
access to food and water and maintained in a 12-hour light/12-hour dark cycle. Genotypes were con-
firmed by PCR amplification of  genomic DNA isolated from toe or tail snip. The conditions for the floxed 
primers (F1/R1 and F2/R2) were as follows: 94°C for 3 minutes; then 32 cycles of  94°C for 30 seconds, 
66°C for 30 seconds, and 72°C for 12 seconds; and then a final extension of  72°C for 7 minutes. To detect 
Cre recombinase, the PCR conditions for Cre for/Cre rev were as follows: 94°C for 3 minutes; then 32 
cycles of  94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 5 seconds; and then a final extension of  
72°C for 7 minutes. The PCR product sizes were as follows: F1/R2 = 616 bp; F2/R2 = 453 bp; Cre for/
Cre rev = 204 bp. We used an initial pair of  GGT1-Cre primers shown in Figure 1B, which were 400 bp in 
size. PCR primer sequences are listed in Table 1.
Murine model of  cisplatin-induced nephrotoxic AKI. Cisplatin nephrotoxic AKI was induced in randomly 
distributed male and female Trip13Stop/Stop and GGT1-Cre+/– Trip13Stop/Stop mice (aged 8–12 weeks). Water was 
removed from the mice for at least 12 hours prior to injecting the mice with a single IP dose of  cisplatin (15 
mg/kg) (Advanced ChemBlocks, catalog K12017) or vehicle (20% captisol dissolved in sterile saline). In some 
mice, mirin (50 mg/kg) or NU7441 (20 mg/kg) was injected into the IP space either immediately or 6 hours 
after the administration of  cisplatin, respectively. Body weights were measured prior to the injection and every 
24 hours for the duration of  the experimental period. Blood was collected by submandibular bleeding after 24 
and 72 hours following the initial injection to isolate plasma for measurement of  creatinine by liquid chroma-
tography–tandem mass spectrometry (Department of  Biochemistry, University of  Alabama at Birmingham) 
and lipocalin-2 by ELISA kit (NGAL; Abcam ab119601). Prior to euthanasia, kidneys were removed and 
placed either in neutral buffered formalin for paraffin embedding or on dry ice for protein isolation.
Chemicals and reagents for NP formulation. Poly(D, l-lactide-co-glycolide) (PLGA) (50:50 lactide-glycolide ratio, 
MW: 31,000–50,000, ester terminated) was purchased from Birmingham Polymers. Poly(vinyl alcohol) (PVA) 
(363138, MW: 30,000–70,000), poly(l-lysine) (PLL) (MW: 30,000–70,000), Pluronic F-68 (P1300, MW: 8350), 
and coumarin 6 (442631, 98%) were purchased from MilliporeSigma and used without further purification.
Preparation and characterization of  PLGA-mirin NPs. PLGA NP formulation with mirin and control 
PLGA NPs were prepared by nanoprecipitation technique (54). Briefly, PLGA (90 mg) with or without 
mirin (50 mg) was dissolved in 10 mL of  acetone to achieve a uniform solution; 2% PVA-aqueous solu-
tion was prepared in cold water, kept under stirring until it dissolved. To this freshly prepared PVA solu-
tion, PLGA-mirin or PLGA-alone hydrophobic solution was added dropwise and stirred on a magnetic 
stir plate at 1000 rpm. The next day, after the acetone evaporated, 10 mg of  PLL and 10 mg of  Pluronic 
F-68 were dissolved in water, added to the NP suspension, and stirred for at least 6–8 hours. The formu-
lation was stored at 4°C until further use. Similarly, ICG-PLGA NPs were prepared by replacing mirin 
for mouse imaging studies (55, 56).
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The particle size (nm) and zeta potential (mV) of  prepared PLGA NPs and PLGA-mirin NPs were 
acquired by dynamic light scattering principle using Zetasizer (Nano ZS, Malvern Instruments) (57). The 
particle size measurements were performed at 25°C using 50 μL of  freshly prepared PLGA NPs diluted 
in 1 mL of  ultrapure water and probe sonicated using VirSonic Ultrasonic Cell Disrupter 100 (The VirTis 
Company) for 30 seconds. Particle size of  formulations was measured in filtered water/PBS/DMEM to 
confirm stability of  the particle in a physiologically relevant environment. The measurement was reported 
from 3 runs (~2 minutes each run). The zeta potential of  NPs (50 μL of  nanoformulation in 1 mL of  1× 
PBS) was measured in triplicate (each reading = 30 runs) by laser Doppler microelectrophoresis technique. 
Fourier transform infrared (FTIR) spectral data of  blank NPs and mirin-loaded PLGA NP formulation 
were obtained from lyophilized solid powders (Labconco Freeze Dry System,–48°C, 133 × 10–3 mbar) (58). 
FTIR spectra of  samples were obtained between 4000 and 650 per cm on the Universal ATR sampling 
Accessory plate using a Spectrum 100 FTIR spectrophotometer.
Tissue distribution of  NPs following IP injection. Athymic male nude mice, 8 weeks old (Jackson Laborato-
ry), were used, and the experiments were conducted in accordance with the IACUC at University of  Ten-
nessee Health Science Center (UTHSC). For this experiment, each of  the 3 mice were injected into the IP 
space with PLGA-NPs containing ICG dye (50 μg). After 24 hours, mice were anesthetized with isoflurane 
and imaged using with a coupled device camera in IVIS XRMS Imaging System (Caliper Life Sciences) 
(55, 56). To confirm the fluorescence intensity from each organ, the mice were euthanized to harvest var-
ious organs for arrangement on a Petri dish. Both in vivo and ex vivo imaging were performed to detect 
fluorescence levels emitted by the PLGA-NP-ICG at an excitation filter of  690 nm for 5000 ms. The data 
were presented in photons per second per square centimeter per steradian (p/s/cm2/sr).
Histopathology. Paraffin-embedded sections (4 μm) were deparaffinized in xylene and rehydrated in 
increasing ethanol percentages to prepare for staining with hematoxylin and eosin. The kidney sections were 
deidentified and scored by a blinded nephrologist with expertise in rodent models of  AKI to assess tubular 
injury. The criteria for damaged tubules included the identification of  flattened epithelia, tubular dilation, and 
cast formation as previously described in our lab (23, 25, 26, 59–61). The injured tubules were calculated as a 
percentage of  the total number of  tubules counted in 3–5 different sections from every animal in each group.
Immunofluorescent histochemistry in kidney sections. Immunohistochemistry was performed on deparaf-
finized kidney sections (4 μm). Antigen retrieval was performed by heating for 45–50 minutes, and slides 
were washed in peroxidase blocking solution for 15 minutes. For sections stained with 8-OH-dG, RNase A 
(Invitrogen, Thermo Fisher Scientific) (20 μg/mL) was added for 60 minutes at 37°C. The tissue sections 
were washed in 1× TBS with 0.08% Triton X-100 for 10 minutes and blocked in 2.5% normal donkey 
serum for 60 minutes. Monoclonal GFP antibody (B-2; 1:100-1:200; Santa Cruz Biotechnology catalog 
sc-9996) or 8-OHdG (1:20 dilution; catalog ab48508; Abcam), and polyclonal Ki67 (catalog 15580, 1:200; 
Abcam), were incubated on the tissues overnight at 4°C. The tissues were washed 3 times in 1× TBS and 
the secondary donkey anti–mouse IgG conjugated with Alexa Fluor 555 (1:250 dilution; catalog A-31570; 
Invitrogen, Thermo Fisher Scientific). To determine specific segments of  the nephron, biotinylated PVA-E 
(1:500 dilution; proximal tubules; Vector Laboratories) or DBA (1:500; collecting ducts) lectin was incubat-
ed onto the sections for 30 minutes at 25°C, then with streptavidin-linked IgG with Alexa Fluor 488 (1:500 
dilution; Invitrogen, Thermo Fisher Scientific, catalog S11223) for 30 minutes. The sections were mounted 
with DAPI and imaged on the EVOS light microscope at 20× to 40× original magnification.
Immunohistochemistry using DAB as the substrate. Immunohistochemistry was performed on deparaffin-
ized kidney sections (4 μm) using a slightly modified protocol from that previously described (26, 61, 62). In 
brief, antigen retrieval was performed by heating for 30–50 minutes, incubating in peroxidase blocking solu-
tion to minimize endogenous peroxidase activity, and tissue permeabilizing in 1× Tris buffer saline con-
taining 0.08% Triton X-100. The following primary monoclonal mouse antibody against PCNA (catalog 
2586; 1:250; Cell Signaling Technology), and primary polyclonal rabbit antibodies against phospho-H2AX 
(Ser139) (catalog 9718; 1:250, Cell Signaling Technology), phospho–histone H3 (Ser10; catalog 9701; 
1:250; Cell Signaling Technology), cleaved caspase-3 (catalog 9661, 1:200; Cell Signaling Technology), 
and Ki67 (catalog 15580, 1:200; Abcam) were used on the kidney sections. Secondary goat anti–rabbit IgG 
(Invitrogen, Thermo Fisher Scientific; 1:250) and goat anti–mouse IgG conjugated to horseradish peroxi-
dase (1:250; Cell Signaling Technology catalog 7076) were used and detected using DAB (MilliporeSigma). 
To determine the localization of  GFP to the proximal tubules, PVA-E (Vector Laboratories B-1125) lectin 
conjugated to biotin was used (1:250). Sections were counterstained with hematoxylin. Pictures were taken 
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with an EVOS light microscope at 20× to 40× original magnification. The percentage of  positive nuclei for 
the target proteins was calculated as a total number of  nuclei.
Western blot analysis. Protein lysates were isolated from the harvested mouse organs by homogeni-
zation in 1× RIPA buffer containing protease and phosphatase inhibitors (Thermo Fisher Scientific) 
followed by differential centrifugation as previously described (26, 61, 62). Western blot analysis was 
performed using a 4%–12% SDS-PAGE gradient gel, then transferred to either PVDF or nitrocellular 
membranes, and bands were detected by chemiluminescence (GE, now Cytiva) using Bio-Rad Chemi-
Doc MP imaging system. Antibodies used in this protocol were as follows: GFP (catalog sc-9996; Santa 
Cruz Biotechnology), FLAG (catalog A8592-1MG; MilliporeSigma), Mad2L1 (catalog 4636, 1:1000; 
Cell Signaling Technology), p31comet (Abcam catalog 150363), TRIP13 (Abcam catalog ab128153), p-p53 
(Ser15) (Cell Signaling Technology catalog 9286), and cyclin B1 (Cell Signaling Technology catalog 
4135). As a loading control, GAPDH (1:1500; Cell Signaling Technology) was used. All the antibodies 
were tested using proteins transferred onto PVDF membranes except for cyclin B1 (nitrocellulose).
Quantitative reverse transcription PCR analysis of  gene expression. Total RNA was extracted using an mRNA 
isolation kit (Invitrogen, Thermo Fisher Scientific), and cDNA was synthesized using SuperScript III 
cDNA synthesis kit. Using 1 μg of  each RNA, quantitative PCR analyses were carried out in duplicate sam-
ples using TaqMan probes, the TaqMan Universal PCR Master Mix (Applied Biosystems, Thermo Fisher 
Scientific), and a Step One Plus Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific). 
The primer set targeting 18S RNA and DNA-PKcs (Mn01342966_g1) was tested on our samples. Relative 
gene expression quantification was calculated according to the comparative threshold cycle method using 
18S rRNA as the endogenous control (63). As a negative control, no template conditions were performed 
for each primer set to ensure the absence of  any spurious DNA amplification by the primer combinations.
Statistics. All data are shown as mean ± SEM. The data were tested for normality with the Kolmogor-
ov-Smirnov test using GraphPad Prism 6.0. Normally distributed data were tested with 1-way ANOVA, 
and subsequent post hoc analysis was performed by Tukey’s multiple-comparison test. Non-normally 
distributed data were tested with the Kruskal-Wallis test for significance among multiple groups followed 
by Dunn’s multiple-comparison test. P ≤ 0.05 was considered significant.
Study approval. Deidentified human kidney sections previously scored as normal or AKI were 
obtained from the University of  Alabama at Birmingham using IRB approval X130124002. All animal 
protocols (AUA 17-032, 18-097, and 19-0102) were approved by the UTHSC IACUC prior to the start 
of  any of  the experiments.
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